Evidence map›Paper›PMID 33491167›Full record

ArticlePharmacoEconomics2021

Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden.

Ronan Mahon, Andrea Lang, Pamela Vo, Jasper Huels, Philip Cooney, Andriy Danyliv, Umakanth Vudumula, Sreelatha Vadapalle, Farooq Maniyar, Peter J Goadsby

Abstract read
PubMed Publisher
In one paragraph

Article in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Ronan MahonValue and Access, Novartis Ireland Limited, Dublin, Ireland. ronan.mahon@novartis.com.
Andrea LangMarket Access, Novartis Sverige AB, Kista, Sweden.
Pamela VoGlobal Patient Access, Novartis Pharma AG, Basel, Switzerland.
Jasper HuelsWW Market Access and HEOR, Novartis Pharma AG, Basel, Switzerland.
Philip CooneyValue and Access, Novartis Ireland Limited, Dublin, Ireland.
Andriy DanylivValue and Access, Novartis Ireland Limited, Dublin, Ireland.
Umakanth VudumulaValue and Access, Novartis Healthcare Private Limited, Hyderabad, India.
Sreelatha VadapalleValue and Access, Novartis Healthcare Private Limited, Hyderabad, India.
Farooq ManiyarBasildon and Thurrock University Hospitals and Queen Mary University, London, UK.
Peter J GoadsbyNIHR-Wellcome Trust King's Clinical Research Facility, SLaM Biomedical Research Centre, King's College London, London, UK.
Novartis (Ireland) · IENovartis (India) · INNovartis (Switzerland) · CHBasildon and Thurrock University Hospitals NHS Foundation Trust · GBKing's College London · GBNovartis (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMigraine is a common neurological disease that disproportionately affects females and has a peak incidence during productive years, resulting in significant burden.

objectiveThe aim of the study was to determine the cost effectiveness of erenumab for the preventive treatment of migraine.

methodsA hybrid decision-tree plus Markov model was developed to evaluate the cost effectiveness of erenumab as a migraine treatment compared with best supportive care only for patients experiencing at least 4 monthly migraine days for whom at least two prior preventive treatments had failed. Clinical efficacy data were based on results from four randomized controlled trials of erenumab against placebo. The primary outcomes were costs, migraine days, and quality-adjusted life-years (QALYs). An incremental cost-effectiveness ratio (ICER) was estimated as the cost per QALY gained. The cost per migraine day avoided was also estimated, as were disaggregated direct and indirect costs. The analysis was conducted from Swedish societal and healthcare system perspectives based on total migraine, chronic migraine and episodic migraine populations, using a discount rate of 3% applied to both costs and health benefits and using year 2019 values.

resultsIn the base-case deterministic analyses, erenumab treatment resulted in ICERs of Swedish krona (SEK) 34,696 (€3310) and SEK301,565 (€28,769) per QALY gained in the total migraine and episodic migraine populations, respectively. Erenumab was dominant in the chronic migraine population. In the total migraine population, the use of erenumab resulted in a net benefit to society of SEK81,739 (€7773) per patient, assuming a willingness-to-pay threshold of SEK300,000 (€28,528) per QALY.

conclusionsOur analysis suggests that erenumab is a cost-effective treatment for migraine with a willingness-to-pay threshold of SEK300,000 per QALY.

Indexed as

Migraine DisordersAntibodies, Monoclonal, HumanizedCost-Benefit AnalysisFemaleHumansSwedenTreatment FailureAntibodies, Monoclonal, Humanizederenumab

Identifiers

PMID33491167
OpenAlexW3126007787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.